This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.
Ticker(s): PFEWho's the expert?
- Board certified, fellowship trained rheumatologist with more than 25 years of experience in the diagnosis and treatment of musculoskeletal disease and systemic autoimmune conditions that affect the joints, muscles, and bones.
- Treats over 60 patients with Rheumatoid Arthritis and has prescibed Xeljanz to over 15 patients
- Diagnose and treat highly complex conditions, including those that affect other organs and systems like the brain, kidneys, blood vessels or lungs. Conditions treated may include rheumatoid arthritis, gout, lupus, osteoarthritis, osteoporosis and fibromyalgia, among many others.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
